When another HA course may be reasonable

Another course of hyaluronic acid may be reasonable for some people with knee osteoarthritis, but mainly where the first course gave clear, worthwhile relief in pain or day-to-day function. In practice, the strongest case is usually someone with early to moderate knee OA who improved after an earlier injection cycle, rather than someone with advanced joint damage looking for a last-step fix. Hyaluronic acid is a symptom-control treatment, not a cartilage-repair treatment, and it should not be treated as a routine next move for every sore knee.

That narrower framing matters because the guidance is split. The 2019 ACR guideline conditionally recommended against hyaluronic acid for knee OA, and AAOS says it is not recommended for routine use, while OARSI allows it more selectively depending on clinical context and comorbidity. So the sensible rule of thumb is not “repeat it because it is available”, but “consider it again if the last course clearly helped, and the aim is temporary symptom relief rather than changing the arthritis itself”.

Published reviews in 2018 and 2022 support that cautious middle ground: repeat courses may help some prior responders, but the best product, number of injections, timing between courses and likely duration of benefit are still not settled. The harder decisions are whether the benefit justifies the cost, when repeating stops making sense, and how much weight to give claims about delaying knee replacement.

What the evidence says about repeat courses

Useful evidence exists, but it is supportive rather than definitive. A 2018 systematic review reported that repeated intra-articular hyaluronic acid courses generally maintained or further improved pain relief, without a reported increase in safety risk across courses. The key practical takeaway is not a fixed timetable for everyone with knee osteoarthritis, but a response test: repeat treatment is easier to justify after a clearly worthwhile first cycle than after a marginal result.

The uncertainty lies in the details that matter at the next decision point. A 2022 systematic review of 38 randomised trials involving 5,025 patients still found no settled answer on the best preparation, the ideal number of injections, when another course should be given, or how long benefit should last. That makes a second course more defensible when the first produced a meaningful improvement in pain or day-to-day function, and less persuasive when the effect was vague or short-lived. Product variation adds another layer: hyaluronic acid preparations are not identical, and some analyses distinguish high- from low-molecular-weight products rather than treating them as interchangeable.

When the cost-benefit case is stronger or weaker

On money and hassle, the useful question is not whether one model found hyaluronic acid to be “cost-effective” on average, but whether it is likely to be worth it in a particular stage of knee osteoarthritis. In one published model, high-molecular-weight hyaluronic acid looked like reasonable value in early to moderate disease, and in some comparisons even came out better overall than lower-molecular-weight products or exercise-based care because the extra symptom relief offset later costs.

The same analysis showed how quickly that picture can change. In late-stage knee OA, value weakened sharply: it held up only in some comparisons when a 50% response rate was assumed, and in a 10% responder worst-case scenario it was not cost-effective. In plain English, HA looks more worthwhile when the arthritis is not too advanced, the product used has better evidence, and relief lasts long enough to cut down repeat appointments, extra medication, or earlier escalation of care.

A 2022 review of 38 trials involving 5,025 patients also noted that product choice, injection number and duration of benefit are still unsettled. That is why “HA is cost-effective” is too blunt a headline; the real issue is value for whom, at what stage, and with what chance of a meaningful response.

Does HA really delay knee replacement

Set aside the symptom-relief question for a moment: the more eye-catching claim is that hyaluronic acid may push back knee replacement. Two large claims-database studies do point that way. In a 2015 U.S. analysis of 182,022 people who eventually had total knee replacement, median time from osteoarthritis diagnosis to surgery was 114 days in non-users versus 484 days in HA users, and the delay was longer with more courses. A 2024 Korean cohort of 36,983 patients also found roughly a 1-year longer time to arthroplasty in HA users, with lower adjusted risk and a cycle-response pattern.

The important limit is simple: these were observational database studies, so they show an association with later surgery, not proof that HA itself caused the delay. Patients selected for injections may have had different baseline severity, different wishes about surgery, different access to orthopaedic care, or clinicians who were already trying to defer arthroplasty.

That leaves a measured conclusion. Repeat HA may help some people postpone surgery discussions, especially if they previously responded and are not yet at the most advanced stage. It is not defensible to say HA reliably delays or avoids knee replacement for everyone with knee OA. In advanced OA, repeated courses may add cost and clinic visits without materially changing the eventual need for arthroplasty.

How to decide with a specialist

Rather than rehearse the guideline debate again, the useful end-point is a short consultation checklist. A 2022 review noted that product choice and the ideal number of injections or repeat courses are still not standardised, so another HA round needs a clear clinical reason behind it rather than vague promises about “lubrication” or delaying surgery.

• Did I get a clear, worthwhile benefit from the last course, and how long did it last?
• How advanced is the osteoarthritis now?
• Which HA product is being proposed this time, and why that one?
• What benefit is realistic on this round, over what time period?
• What would count as a failed repeat course?
• If the last response was weak or brief, what are the alternatives now?

That conversation matters because the professional bodies do not line up neatly. The 2019 ACR guideline and AAOS are more sceptical about routine HA use, while OARSI allows it more selectively depending on the clinical setting. In practical terms, the case for repeating HA may be stronger in earlier-stage OA and weaker once disease is more advanced or prior response was poor. If that rationale is still unclear, Search MSK lists specialists across the UK who assess knee osteoarthritis and offer injection treatments, with filters by region and specialty.